JAZZ PHARMACEUTICALS PLC (JAZZ)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for JAZZ
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| JAZZ | Director, Gilead Sciences, Inc., Royalty Pharma plc, and Structure Therapeutics Inc.; Member | 67 | ["More than 30 years of biopharmaceutical leadership","Expertise in drug development","Commercialization","Public policy"] | ["Audit Committee","Compensation Committee","Nominating Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GILD | Former Chair of Board of Directors, Biotechnology Innovation Organization | 67 | ["Significant leadership experience in the biopharma industry, including serving as a chief executive officer of a global healthcare company", "Physician with a strong scientific background, known for championing access to care"] | ["Audit Committee"] | 2026 |
| BIO | Executive Vice President, Research and Development | 53 | ["technical, financial and business expertise", "years as a researcher", "executive and director of various public companies"] | [] | 2012 |
Biography sourced from the proxy statement filing.
Ted W. Love has served as a member of our Board since December 2025. Dr. Love served as president and CEO of Global Blood Therapeutics, Inc., a global biopharmaceutical company, from 2014 until its acquisition by Pfizer Inc. in 2023. Previously, Dr. Love served as Executive Vice President of R&D and technical operations at Onyx Pharmaceuticals, Inc., a pharmaceutical company, and President, CEO/chairman of Nuvelo, Inc., a biopharmaceutical company. Dr. Love began his biotechnology career at Genentech, Inc., a global biotechnology company, where he held several management positions. Dr. Love currently serves on the boards of biopharmaceutical companies Gilead Sciences, Inc., Royalty Pharma plc, and Structure Therapeutics Inc., and is the immediate past chair of the Biotechnology Innovation Organization board of directors. He earned a B.A. in molecular biology from Haverford College and his medical degree from Yale Medical School, followed by a residency in internal medicine and a fellowship in cardiology at Massachusetts General Hospital.